CTLA4 and type 1 diabetes mellitus: Specific HLA haplotypes and polymorphisms in the CTLA-4 and PD-1 genes have been associated with an increased risk of autoimmune β cell destruction and the onset of type 1 diabetes mellitus (T1DM) following ICI therapy [66].